Anti-HIV-1 seroreactivity and HIV transmission route[R1]
Autor(a) principal: | |
---|---|
Data de Publicação: | 1999 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da FIOCRUZ (ARCA) |
Texto Completo: | https://www.arca.fiocruz.br/handle/icict/787 |
Resumo: | Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals. |
id |
CRUZ_466d309c0f654511e05b3461475ce8bf |
---|---|
oai_identifier_str |
oai:www.arca.fiocruz.br:icict/787 |
network_acronym_str |
CRUZ |
network_name_str |
Repositório Institucional da FIOCRUZ (ARCA) |
repository_id_str |
2135 |
spelling |
Bongertz, VeraGuimarães, Monick LindenmeyerCosta, M. F. G. Soares daSantos, Valdiléa Gonçalves Veloso dosBastos, Francisco Inácio Pinkusfeld MonteiroSzwarcwald, Celia LandmannDerrico, MonicaDias, Paulo Roberto Telles PiresPilotto, Jose Henrique da SilvaJoão Filho, Esaú CustódioMorgado, Mariza Gonçalves2010-08-23T16:58:49Z2010-11-04T14:20:09Z2010-08-23T16:58:49Z2010-11-04T14:20:09Z1999BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999.1386-6532https://www.arca.fiocruz.br/handle/icict/787Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals.Research supported by the FIOCRUZ Integrated AIDS Program PIAF, World Bank 063:94, CNPq 520922:95-6 and CNPq:MRC(Canada).Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro Centro de Informação Cientifica e Tecnológica. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Informação Cientifica e Tecnológica Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Centro de Informação Cientifica e Tecnológica. Rio de Janeiro, RJ, BrasilUniversidade Estadual do Rio de Janeiro. NEPAD. Rio de Janeiro, RJ, BrasilHospital Geral de Nova Iguaçu. Rio de Janeiro, RJ, BrasilHospital dos Servidores do Estado. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Oswaldo Cruz. Hospital Evandro Chagas. Laboratório de AIDS e Imunologia Molecular. Rio de Janeiro, RJ, BrasilengElsevier Science B.V.Anti-HIV-1 seroreactivity and HIV transmission route[R1]info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHIVSeroreactivityTransmissionGenotypesinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZTEXTLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.txtLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.txtExtracted texttext/plain37624https://www.arca.fiocruz.br/bitstream/icict/787/6/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.txt209dbb840deada7e4ad84c8850f2f8e8MD56ORIGINALLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdfapplication/pdf115488https://www.arca.fiocruz.br/bitstream/icict/787/2/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf822ef0044d528414151cf2fc097db530MD52LICENSElicense.txttext/plain1848https://www.arca.fiocruz.br/bitstream/icict/787/3/license.txt9bb8f65f67107ba6a95f9f2a8ded1f54MD53THUMBNAILLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.jpgLANDMANN_BASTOS_Anti-HIV Seroreactivity_1999.pdf.jpgGenerated Thumbnailimage/jpeg1971https://www.arca.fiocruz.br/bitstream/icict/787/5/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.jpg5ed5d5af2bc10273beea5568c5ae8814MD55icict/7872023-08-23 13:24:56.324oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-08-23T16:24:56Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.pt_BR.fl_str_mv |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
title |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
spellingShingle |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] Bongertz, Vera HIV Seroreactivity Transmission Genotypes |
title_short |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
title_full |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
title_fullStr |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
title_full_unstemmed |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
title_sort |
Anti-HIV-1 seroreactivity and HIV transmission route[R1] |
author |
Bongertz, Vera |
author_facet |
Bongertz, Vera Guimarães, Monick Lindenmeyer Costa, M. F. G. Soares da Santos, Valdiléa Gonçalves Veloso dos Bastos, Francisco Inácio Pinkusfeld Monteiro Szwarcwald, Celia Landmann Derrico, Monica Dias, Paulo Roberto Telles Pires Pilotto, Jose Henrique da Silva João Filho, Esaú Custódio Morgado, Mariza Gonçalves |
author_role |
author |
author2 |
Guimarães, Monick Lindenmeyer Costa, M. F. G. Soares da Santos, Valdiléa Gonçalves Veloso dos Bastos, Francisco Inácio Pinkusfeld Monteiro Szwarcwald, Celia Landmann Derrico, Monica Dias, Paulo Roberto Telles Pires Pilotto, Jose Henrique da Silva João Filho, Esaú Custódio Morgado, Mariza Gonçalves |
author2_role |
author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Bongertz, Vera Guimarães, Monick Lindenmeyer Costa, M. F. G. Soares da Santos, Valdiléa Gonçalves Veloso dos Bastos, Francisco Inácio Pinkusfeld Monteiro Szwarcwald, Celia Landmann Derrico, Monica Dias, Paulo Roberto Telles Pires Pilotto, Jose Henrique da Silva João Filho, Esaú Custódio Morgado, Mariza Gonçalves |
dc.subject.en.pt_BR.fl_str_mv |
HIV Seroreactivity Transmission Genotypes |
topic |
HIV Seroreactivity Transmission Genotypes |
description |
Background: antibody binding assays carried out by our group have consistently indicated a higher reactivity of sera from male HIV-1 infected individuals. This study was carried out in order to analyze the importance of gender, route of transmission, disease progression and HIV-1 genotype in seroreactivity assays. Study design: specificity of antibody binding was studied in plasma of 247 HIV-1 seropositive individuals belonging to patient groups of pregnant women, injecting drug users (IDUs) and recent seroconvertors, resident in Rio de Janeiro, RJ. Recognition of synthetic peptides corresponding to antigenically important epitopes in the envelope of HIV-1 (gp41 immunodominant epitope, V3 loop, V2 loop and gp41 735–752 epitope) was determined. Results: the immunodominant gp41 peptide (amino acids 594–613, HIV-1 MN sequence) was recognized by 85% of all plasma tested. Reactivity with the gp41 735–752 peptide and gp120 V2 loop peptides was low but quite variable, being generally more often specific to a Brazilian V2 peptide used than to the HIV-1 MN derived V2 peptide. The overall recognition of the different V3 peptides tested varied from 41 to 76%. Patients with more advanced disease showed a more frequent reactivity with the peptides studied than did asymptomatic patients. Statistically significant differences in peptide recognition were observed by multiple logistic analyses comparing plasma derived from individuals infected by blood or sexual HIV transmission, adjusting for disease progression and gender. Plasma from individuals infected by sexual transmission showed lower peptide recognition than did plasma from individuals infected through HIV positive blood. Association attempts between seroreactivity and genotype indicated that plasma derived from patients infected with HIV-1 of the F subtype showed highest recognition of heterologous V3 peptides, as well as a slightly more frequent recognition of the non-V3 peptides tested. Recognition of homologous peptides was generally higher than recognition of heterologous peptides. Differences were most pronounced between the prototypical HIV-1 B subtype and the Brazilian B′′ variant of this subtype but almost non-existent between the HIV-1 B and F subtypes. Conclusions: individual gender was shown to be a confounder when investigating the relationships of peptide reaction to HIV-1 route of transmission through multivariate statistical methods: patients infected by blood transmission (IDU) present higher frequency of peptide recognition than individuals infected by sexual HIV-1 transmission. Plasma from individuals infected with the B′′ variant (GWG) of B subtype HIV-1 showed lower heterologous peptide recognition than that from HIV-1 B (GPG) or F infected individuals. |
publishDate |
1999 |
dc.date.issued.fl_str_mv |
1999 |
dc.date.accessioned.fl_str_mv |
2010-08-23T16:58:49Z 2010-11-04T14:20:09Z |
dc.date.available.fl_str_mv |
2010-08-23T16:58:49Z 2010-11-04T14:20:09Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999. |
dc.identifier.uri.fl_str_mv |
https://www.arca.fiocruz.br/handle/icict/787 |
dc.identifier.issn.pt_BR.fl_str_mv |
1386-6532 |
identifier_str_mv |
BONGERTZ, V. et al. Anti-HIV-1 seroreactivity and HIV transmission route[R1]. Journal of Clinical Virology, v. 12, p. 27–36, 1999. 1386-6532 |
url |
https://www.arca.fiocruz.br/handle/icict/787 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Elsevier Science B.V. |
publisher.none.fl_str_mv |
Elsevier Science B.V. |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Repositório Institucional da FIOCRUZ (ARCA) |
collection |
Repositório Institucional da FIOCRUZ (ARCA) |
bitstream.url.fl_str_mv |
https://www.arca.fiocruz.br/bitstream/icict/787/6/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.txt https://www.arca.fiocruz.br/bitstream/icict/787/2/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf https://www.arca.fiocruz.br/bitstream/icict/787/3/license.txt https://www.arca.fiocruz.br/bitstream/icict/787/5/LANDMANN_BASTOS_Anti-HIV%20Seroreactivity_1999.pdf.jpg |
bitstream.checksum.fl_str_mv |
209dbb840deada7e4ad84c8850f2f8e8 822ef0044d528414151cf2fc097db530 9bb8f65f67107ba6a95f9f2a8ded1f54 5ed5d5af2bc10273beea5568c5ae8814 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
repositorio.arca@fiocruz.br |
_version_ |
1798324688634511360 |